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Matrix metalloproteinases (MMPs) produced from macrophages contribute to plaque rupture, 
atherothrombosis and myocardial infarction. New treatments could emerge from defining the 
mediators and underlying mechanisms. In human monocytes, prostaglandinE2 (PGE2) stimulates 
MMP production and inflammatory mediators such as TNFα, IL-1 and toll-like receptor ligands can 
act either through or independently of PGE2. Differentiation of human monocytes to non-foamy 
macrophages increases constitutive expression of MMPs-7, -8, -9, -14 and -19 and TIMPs-1 to -3 
through unknown, PGE2-independent mechanisms. Human macrophages express more MMPs-1, -7, 
-9 and TIMP-3 and less MMP-12 and -13 than mouse macrophages. Inflammatory mediators working 
through AP-1 and NF-κB transcription factor pathways upregulate MMPs-1, -3, -10, -12 and -14 in 
human macrophages (MMP-9, -12 and -13 in mice) and studies with plaque tissue sections and 
isolated foam cells confirm this conclusion in vivo. Classical activation with GM-CSF upregulates 
MMP-12, whereas IFNγ upregulates MMPs-12, -14 and -25 and downregulates TIMP-3 in human but 
not mouse macrophages. Alternative activation with IL-4 markedly stimulates the expression of only 
MMP-12 in humans and MMP-19 in mice. Anti-inflammatory cytokines, IL-10 and TGFβ, decrease 
production of several MMPs.  Epigenetic upregulation of MMP-14 during foam cell formation or by 
GM-CSF occurs by decreasing miRNA-24. A ‘perfect storm’ caused by a combination of these 
mechanisms most likely promotes MMP-mediated macrophage invasion, tissue destruction and 
atherosclerotic plaque rupture.  
Introduction 
Production of matrix metalloproteinases (MMPs) from macrophages contributes to destruction of 
the extracellular matrix (ECM) in a broad range of chronic inflammatory diseases. Atherosclerosis is a 
special case because lipoprotein particles trapped in the artery wall recruit monocytes that convert 
to foam-cell macrophages by engorging oxidised and other modified forms of these lipoproteins 
(Williams & Tabas, 1995). In advanced atherosclerosis, plaques consisting of amorphous lipid 
deposits with overlying, expanded connective tissue can obstruct the coronary and other conduit 
arteries, leading to stable ischaemic syndromes, including angina pectoris. Moreover, depletion of 
collagen and other ECM molecules from the core and fibrous cap overlying plaques can lead to loss 
of mechanical competence, culminating in rupture of the cap, thrombus formation on the exposed 
thrombogenic core and partial or complete occlusion of the lumen (Libby, 2013). Plaque rupture 
underlies the majority of myocardial infarctions (MIs) and strokes (Virmani et al., 2006), which 
together constitute the principal cause of death in many advanced societies. Inhibiting MMP activity 
(Newby, 2012; Newby, 2015), or the mechanisms responsible for production of MMPs from 
macrophages (reviewed here), therefore represent viable targets for therapies to prevent MIs and 
strokes. The earlier literature relating to this topic was previously discussed exhaustively (Newby, 
2008), and hence this article seeks to provide an update by emphasizing findings during the last 
seven years. These new insights suggest that multiple inflammatory mediators need to act in concert 
to raise a ‘perfect storm’ that provokes net destruction of the ECM leading to MIs and strokes.   
Involvement of matrix metalloproteinases in atherosclerosis 
There are at least 23 MMP enzymes, most of which are secreted, except the six membrane-type 
MMPs that are inserted into or attached to the external membrane surface. The catalytic sites of 
MMPs may be blocked by all or at least some of the four tissue inhibitors of MMPs (TIMPs) 
(reviewed in detail elsewhere (Nagase et al., 2006)). A structurally-similar active catalytic domain 
occurs also in some members of the disintegrin metalloproteinases (ADAMs) and in the ADAMs with 
thrombospondin domains (ADAM-TSs). MMPs have the ability to degrade a variety of ECM 
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components but also many other cell surface, secreted or ECM-sequestered substrates many of 
which regulate inflammation (Khokha et al., 2013).   
As summarized previously (Newby, 2012; Newby, 2015), the evidence that MMPs play pathological 
roles in atherosclerosis comes partly from rabbit and especially mouse models. However, the 
expression pattern of MMP mRNAs in human blood and mouse bone marrow macrophages isolated 
and classically activated under very similar conditions is quite divergent, with far more MMPs-1, -7, -
9 and TIMP-3 in human macrophages but much less MMP-12 and -13 compared to mouse (Newby, 
2015).  This conclusion is reinforced by other studies of mouse bone marrow macrophages and 
Raw264.7 cells (Hald et al., 2012; Murray et al., 2013). Moreover, a comparison of unstimulated 
mouse and human blood monocytes and macrophages shows the same similarities and differences 
(Fig. 1). Differentiation of blood monocytes to macrophages greatly increases expression of MMPs in 
both mice and humans (Fig. 1) but levels of MMPs-1, -7, and -9 and TIMPs-1 and -3 are much higher 
in man (Huang et al., 2012), whereas MMPs-12, -13 and -23 are much higher in mice (Tsaousi et al., 
2016). The high levels of MMP-12 and -13 expression in mice macrophages correspond with 
dramatic effects on atherosclerosis (Johnson et al., 2011; Quillard et al., 2011). However, MMP-12 
(Scholtes et al., 2012) and MMP-13 (Molloy et al., 2004) have restricted expression in human 
atherosclerotic plaques, which invites caution over the clinical translation of the mouse studies.  In 
the case of MMP-12 there are genome wide association studies (GWAS) studies supporting a 
causative role in strokes (Traylor et al., 2014) but this is not the case for MMP-13. Conversely, MMP-
7 is hardly expressed in mouse macrophages and has a modest impact on atherosclerosis (Johnson 
et al., 2005) but could be more important in man (Fig. 1). Most recently, MMP-28 was shown to 
affect macrophage functions in mice (Ma et al., 2013) but MMP-28 is not expressed actively in 
human monocytes or macrophages (Bar-Or et al., 2003). Furthermore, the profound morphological 
differences and the need for high level transfer of fully active forms of MMPs to provoke plaque 
rupture in mice (Gough et al., 2006; Liang et al., 2006) discourage extrapolation to the human 
disease.  
GWAS provides convincing evidence of a pathogenic role for MMP-12 (Traylor et al., 2014) and the 
distantly-related ADAMTS-7 (Reilly et al., 2011). For other MMPs and TIMPs only correlative 
evidence is available so far. For example, many MMPs and TIMPs are overexpressed in human 
atherosclerotic plaques compared to normal tissues (reviewed in detail elsewhere (Newby, 2005)). 
More persuasively, MMP-8, -9, -12 and -14 have been shown in biobank studies to associate with 
plaque morphologies suggesting vulnerability to rupture, whereas MMP-2 and TIMP-3 show 
negative association (Sluijter et al., 2006; Peeters et al., 2011; Scholtes et al., 2012; Johnson et al., 
2014). Furthermore, at least MMP-8 and MMP-12 levels in plaques are risk factors for subsequent 
adverse cardiovascular events (Peeters et al., 2011; Scholtes et al., 2012). In future it may be 
possible to combine biochemical and genetic analyses for example in Mendelian Randomisation 
studies or by the identification of rare null mutations. In the meantime a causative role for MMPs in 
human plaque rupture is highly plausible but still a hypothesis. 
Monocyte and macrophage diversity in atherosclerosis 
Production of monocytes and macrophages from myeloid precursors relies on the trophic effects of 
colony stimulating factor (CSF-1). Deletion of CSF-1 or blocking its receptor in mice prone to 
atherosclerosis greatly reduces plaque formation (Di Gregoli & Johnson, 2012). Similarly, depletion 
of monocytes and macrophages in the early stages of mouse atherosclerosis abolishes foam cell 
formation and reveals the accumulation of lipoprotein deposits in susceptible sites (Paulson et al., 
2010).  These experiments establish that macrophages derived from circulating monocytes are 
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required to clear lipoprotein deposits retained in the ECM and that this leads to foam cell formation. 
Some contribution from macrophage proliferation (Robbins et al., 2013) or from expansion of 
resident stem cell populations has also been debated (Nguyen et al., 2012); and additional foam cells 
can be generated by transdifferentiation of resident vascular smooth muscle cells (VSMCs) 
(Shankman et al., 2015). As reviewed previously (Newby, 2005), both macrophages and VSMCs 
elaborate MMPs and TIMPs. Moreover, MMPs and other proteases promote VSMC migration and 
proliferation so as to establish the fibrous cap of plaques.  On the other hand, the high levels of 
many MMPs produced by macrophages (see below) may provoke destruction of the ECM causing 
plaque rupture. 
At least two phenotypes of monocytes (Ly6Chi, CCR2hi, and Ly6CloCXCR3hi) and three phenotypes 
of human monocytes (CD14hiCD16lo, CD14dimCD16lo and CD14dimCD16hi) have been 
characterised (Ziegler-Heitbrock et al., 2010). Despite performing different functions in relation to 
acute inflammation and patrolling behaviour, both monocyte phenotypes appear to contribute to 
atherosclerosis in mouse models (Combadiere et al., 2008). Moreover they do not seem to give rise 
to different macrophage populations in plaques (Tacke et al., 2007).  
Differentiated macrophages adopt a host of different phenotypes. These were initially divided into 
pro-inflammatory, so-called classically activated or M1 type, or anti-inflammatory, so-called 
alternatively activated or M2 type. However, the M1/M2 dichotomy has more recently been 
replaced with more nuanced descriptions of phenotypes (Murray et al., 2014) based on the 
activating mediators and their related signalling pathways some of which are illustrated in Fig. 2.   
Regulation of MMP and TIMP production from monocytes and 
macrophages 
Binding of transcription factors of the activator protein-1 (AP-1) family to regulatory elements in the 
proximal promoters of many MMPs appears to be of central importance for their transcriptional 
regulation, and certainly contributes to their increased production during inflammation (Clark et al., 
2008). However, not all MMP promoters contain proximal AP-1 sites or even a TATA box, which is 
necessary for induced transcription of most genes (Clark et al., 2008). Moreover, a plethora of other 
proximal transcription factors binding sites, including for specificity protein-1 (SP-1), nuclear factor-
κB (NF-κB) and signal transducer and activator of transcription-1 (STAT-1), mediate inflammatory 
activation of several MMPs (Clark et al., 2008). Synergy between activation of AP-1 and NF-κB is 
responsible for induction of several MMPs in a variety of cell types (reviewed in (Newby, 2005)), 
including macrophages.  This may depend on a signalosome that brings together widely separated 
transcriptional activators including distal enhancer or suppressor elements (Glass & Natoli, 2015).  
In order to influence MMP and TIMP expression therapeutically in plaques and other inflammatory 
foci, it would be valuable to identify the key mediators and also the underlying mechanisms.  This 
review will attempt to synthesise the available information, in part by providing a searchable 
databases for monocytes (Supplementary Table 1) and macrophages (Supplementary Table 2). 
ProstaglandinE2 and the cAMP pathway 
ProstaglandinE2 (PGE2) mediates upregulation of at least MMP-1, -7, -9, -10 and -14, as well as 
TIMP-1 in undifferentiated human monocytes, as previously reviewed (Newby, 2008). PGE2-
dependent MMP up-regulation has also been observed in human alveolar macrophages, mouse 
peritoneal macrophages and RAW264 cells (see Supplementary Tables 1 and 2). As shown in Fig. 2, 
action of inflammatory mediators or integrin-mediated binding to various ECM components 
activates phospholipase C, which releases arachidonic acid.  This is transformed by the sequential 
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activity of cyclooxygenase (COX) and PGE2 synthase (PGES-1) to PGE2. COX-1 is constitutively 
expressed in human monocytes and COX-2 is rapidly upregulated by adherence or LPS (Reel et al., 
2011) or by TNFα together with GM-CSF (Zhang & Wahl, 2015). PGE2 acts specifically on EP4 
receptors to stimulate cAMP formation, which then activates transcription through direct binding of 
cAMP response element binding protein (CREB) to the MMP-1 promoter or by enhancing the binding 
NF-κB to the MMP-9 promoter (Lai et al., 2003). Work from other cell types also identifies cross-talk 
with the mitogen activated protein kinases (MAPKs) (Gerits et al., 2008) that could promote AP-1 
binding (Fig. 2). Other activators of PGE2-dependent MMP production include extracellular MMP-1 
or MMP-3, which can cleave active TNFα from the surface of mouse peritoneal macrophages, 
leading to MMP-9 secretion (Steenport et al., 2009).  Furthermore, TNFα generated in this way 
upregulates early growth response protein 1 (EGR-1), which induces mPGES-1 expression (Khan et 
al., 2012).  Exposure to Mycobacterium tuberculosis infection can also upregulate MMP-1 but not 
MMP-7 in a PGE2-dependent manner (Rand et al., 2009).  
Differentiation of monocytes to macrophages 
MMPs-2, -7, -9, -11, -12 and -14 and TIMPs-2 and -3 are selectively upregulated in human MCSF-
differentiated macrophages, independently of COX, MAP kinases or NF-κB (Reel et al., 2011), and 
MMP-8, -13, -19, -23 and -25 are also increased in mouse macrophages (Tsaousi et al., 2016). 
Increased expression of MMP-14 has been ascribed to upregulation of the SAF-1 transcription factor 
(reviewed in (Newby, 2008)) but the other mechanisms remain to be clarified. 
Foam cell formation 
The properties of foam cells formed from differentiated macrophages in vitro depends on the source 
of lipid (e.g. platelets, acetylated LDL, minimally or extensively oxidised LDL). Hence widely different 
results have been obtained suggesting stimulation, inhibition or little effect on levels of MMPs 
(Supplementary tables 1 and 2). Stimulation could result from (weak) action on toll like receptors 
(Lundberg & Yan, 2011), whereas inhibition of MMP-9 expression in U937 cells (Supplementary 
Table 1) resulted from formation of peroxisome proliferation activator receptorγ (PPARγ) ligands. 
We found no effect of oxidised LDL on mRNA levels of MMPs and TIMPs but foam cells expressed 
more MMP-14 and less TIMP-3 protein, which implicated epigenetic mechanisms in part mediated 
by microRNA24 (Johnson et al., 2014). In vivo results are also divergent. Rabbit granuloma foam cells 
showed increased MMP-1, -3, -12, -14 and decreased TIMP-3 expression (Supplementary Table 2), 
although mouse granuloma foam cells showed no changes (Thomas et al., 2015) and peritoneal 
foam cells had decreased MMP-13 expression, owing to activation of the LXR nuclear receptor by 
the cholesterol pathway intermediate desmosterol (Spann et al., 2012). So far only the rabbit studies 
investigated protein levels, which might vary despite similar mRNA expression if epigenetic 
mechanisms intervene (Johnson et al., 2014).   
Classical macrophage activators and the AP-1/NF-κB pathway 
The pro-inflammatory mediators TNFα, IL-1β, CD40L and pathogen associated molecular patterns 
that act at several toll-like receptors have been observed to stimulate MMP expression in both 
monocytes and macrophages (Supplementary Tables 1 and 2). Moreover, activation of TLR-2 was 
implicated directly in MMP-1 and MMP-3 production from isolated human plaque-derived cells 
examined ex vivo (Monaco et al., 2009).  These inflammatory mediators share the ability to activate 
the MAP kinases, extracellular related kinases 1/2 (ERKs1/2), p38 MAP kinase and c-jun N-terminal 
kinase (JNK), as well as phophoinositide-3 kinase (PI3 kinase) and the inhibitor of κB kinase2 (IKK2) 
that leads to activation of NF-κB (Fig. 2). Not surprisingly, therefore inhibitors of one or more these 
kinases generally reverse the effects of this broad class of inflammatory mediators (Supplementary 
Tables 1 and 2). However, the precise identity of the activating kinases seems to depend on the 
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MMP and the source of cells (Supplementary Tables 1 and 2). One complicating factor is the 
participation to greater or lesser degree of PGE2 derived from COX-2 (Fig. 2), induction of which 
requires all these kinases (Huang et al., 2012). For example, inhibition of p38 reduced MMP-1 
expression in a PGE2 dependent manner in human monocytes, whereas inhibition of ERKs1/2 
decreased both MMP-1 and MMP-9 expression independently of PGE2 (Zhang & Wahl, 2015).  In the 
absence of PGE2, upregulation of MMP-1 and -10 in human blood derived monocytes depended on 
ERKs1/2, JNK and IKK2 but not p38 MAP kinase (Reel et al., 2011).  The same was true for LPS 
induction of MMP-1, -3, -10, -12 and -14 in human macrophages but induction of MMP-25 required 
p38 (Huang et al., 2012). Furthermore, specificity for the various activating kinases may depend on 
the specific inflammatory signal. For example, induction of MMP-1 in human alveolar macrophages 
by M. tuberculosus depends selectively on p38 MAP kinase (Rand et al., 2009).  Both basal and 
induced expression of many MMPs, especially MMPs-1, -3, -10 and -13 and TIMP-3 is reduced by 
inhibitors of PI3 kinase in human macrophages (Huang et al., 2012).  However, the basis for these 
effects is still not clarified. Other inflammatory mediators such as clusterin (Shim et al., 2011) or 
complement component C5a (Speidl et al., 2011), or homophylic interactions of  CD147 (EMMPRIN) 
or with its ligand cyclophylin A (Yang et al., 2008) also employ MAP kinases, PI3 kinase, IKK2 and the 
resultant activation of AP-1/NF-κB signalling to upregulate MMPs (Fig. 2).  To confirm that these 
signalling pathways contribute to increased MMP expression in human atherosclerotic plaques, we 
demonstrated co-localisation of activated NF-κB with MMP-1 and MMP-10 (Huang et al., 2012). 
Interferons and the JAK/STAT pathway 
Earlier studies demonstrated profound inhibitory effects of IFNγ on MMPs-1, -3, -9, and -12 and 
TIMP-1 production from human monocytes and macrophages (Supplementary Tables 1 and 2). On 
the other hand, IFNγ acting through the JAK/STAT pathway can upregulate MMP-12, -14 and -25 and 
suppresses TIMP-3 mRNA expression in human macrophages (Huang et al., 2012).  The effect on 
MMP-25 may be especially interesting in view of its ability to modulate the activity of several 
chemokines (Marco et al., 2013).  Given that many human plaques contain IFNγ, induction of MMP-
14 and suppression of TIMP-3 could promote the invasive and destructive MMP14+TIMP-3- 
macrophage phenotype that we detected in rabbit and human foam cells (Johnson et al., 2008).  
Effects of IFNγ appear to be very different in human and mouse macrophages (Hayes et al., 2014), 
which complicates the interpretation of the mouse models. Nevertheless, inhibition of mouse 
macrophage MMP-9 production by IFNγ correlated with slower ECM degradation and thrombus 
resolution in wild type compared to IFNγ knockout mice in a model of deep vein thrombosis (Nosaka 
et al., 2011). Deletion of TGFβ receptors in T-lymphocytes, which promotes polarization to the 
Thelper1 phenotype that releases IFNγ also decreased MMP-9 expression in atherosclerotic mouse 
aortas (Ovchinnikova et al., 2009). On the other hand, MMP-13 was increased, suggesting that IFNγ 
from Thelper1 cells can promote as well as inhibit expression of different MMPs.  In other 
experiments, deletion of all T and B cells (Hayes et al., 2014) or just Thelper1 cells (Tsaousi et al., 
2016) did not affect MMP or TIMP expression in mouse foam cells from subcutaneous granulomas or 
in atherosclerotic plaques.  Consequently, the evidence for stimulatory effects of IFNγ on MMP 
expression is stronger in humans than mice.  
IL-6 and GM-CSF 
As illustrated in Fig. 2, IL-6 activates JAK1 and STAT-3, MAP kinases and PI3 kinases (Schaper & Rose-
John, 2015), which may account for its upregulation of MMPs (Supplementary Tables 1 and 2). 
Interestingly, induction of MMP-9 in mouse macrophages by IL-6 is independent of COX-2 (Kothari et 
al., 2014).  
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GM-CSF signals through the CSFR2 complex to activate JAK2 and STAT-5 as well as MAP kinases and 
PI3 kinases (Broughton et al., 2012).  Hence the transcriptional programme initiated by GM-CSF is 
unique, although it replicates some aspects of both the classical and alternative paradigms. GM-CSF 
is especially associated with upregulation of MMP-12 (Supplementary Table 1), which occurs 
through activation of the proximal AP-1 site. Why this direct action of GM-CSF is selective for MMP-
12 over other MMPs with proximal AP-1 sites is unclear. GM-CSF can also induce TNFα secretion 
leading to the upregulation of other MMPs (Zhang et al., 1998). Given this and the fact that GM-CSF 
can be upregulated by oxidised LDL and several inflammatory mediators (Di Gregoli & Johnson, 
2012), GM-CSF-stimulated and classically-activated macrophage phenotypes are probably an 
overlapping in vivo. Despite this, in mice exposed to cigarette smoke, neutralisation of GM-CSF 
selectively decreases MMP-12 but not MMP-9 activity in lung macrophages (Vlahos et al., 2010). 
GM-CSF increases MMP-14 protein expression and activity independently of changes in mRNA 
expression but because micro-RNA24 is decreased, which relieves an inhibitory effect on protein 
translation (Di Gregoli et al., 2014). These observations are particularly interesting because there is 
evidence for distinct populations of M-CSF and GM-CSF macrophages in human plaques that may 
make different contributions to plaque stability (Di Gregoli & Johnson, 2012). Indeed, GM-CSF action 
might also account for the harmful MMP14+TIMP-3- macrophage phenotype (Johnson et al., 2008) 
Hypoxia 
Most macrophages in atherosclerotic plaques are in a chronic state of hypoxia (Sluimer et al., 2008). 
Hypoxia increases expression of MMP-7 (Supplementary Table 2). Transcriptomic data from hypoxic 
macrophages indicates that, MMPs-1, -3, -10 and -12 are also significantly upregulated, perhaps 
secondarily to increased production of IL-1α,β (Fang et al., 2009). Pathways through hypoxia 
inducible factor-1α (HIF-1α) (Lee et al., 2012), HIF-2α (Yang et al., 2010) and JAK2/STAT-3 have been 
implicated (Gao et al., 2015).  
Anti-inflammatory pathways 
Priming with IL-4 inhibitors expression of MMP-1, MMP-9 and TIMP-1 in monocytes and 
macrophages (Supplementary Tables 1, 2), perhaps owing to overexpression of suppressor of 
cytokine signalling (SOCS) proteins. However, consistent with previous work in mouse macrophages 
(Supplementary Table 2), we found that IL-4 selectively increases MMP-12 in human monocyte 
derived macrophages (Huang et al., 2012). MMP-25 and TIMP-3 were also up-regulated (Huang et 
al., 2012) but the mechanisms responsible remain unclear. IL-10 also antagonises the upregulation 
of MMP-1 and MMP-9, but unlike IL-4 it increases expression of TIMP-1 (Supplementary Tables 1 
and 2).  Again the intermediary action of SOCS proteins appears reasonable but remains to be fully 
documented. IL-10, in particular, is abundant in atherosclerotic plaques and therefore most likely 
exerts a physiological dampening effect on MMP activity.  TGFβ inhibits MMP-12 production in 
human monocytes (Supplementary Table 1). However, TGFβ can both stimulate and inhibit MMP-2 
and MMP-9 secretion from mouse peritoneal macrophages (Ogawa et al., 2011). Upregulation of 
MMP-9 by TGFβ has been recently ascribed to stimulation of PI3K leading to activation of AP-1 
transcription factors (Haidar et al., 2015). Activation of several anti-inflammatory nuclear hormone 
receptors inhibits MMP production (see Supplementary Tables 1 and 2). For example, PPARα 
selectively inhibits IL-1β induced MMP-12 production by direct binding to components of the AP-1 
complex (Souissi et al., 2008), whereas both PPARα and PPARγ inhibit MMP-9 secretion from human 
macrophages (Supplementary Table 2). PPARγ agonists protect against the macrovascular 
complications of diabetes (Dormandy et al., 2005) and inhibition of MMP activity could play an 
important part in this action. Statins, the mainstay of atherosclerosis prevention, have also been 
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shown to inhibit the expression of a broad range of MMPs by both transcriptional and post-
transcriptional mechanisms (reviewed in (Newby, 2008)). 
Conclusions: the combined action of multiple mediators causes MMP 
up-regulation and plaque rupture 
Animal and human data supports the concept that an excess of MMP over TIMP production from 
macrophages and foam cells contributes to atherosclerotic plaque growth and rupture. In rabbit and 
mouse models, several MMPs promote plaque progression and affect plaque morphology in ways 
consistent with greater vulnerability to rupture. Furthermore, foam cell macrophages in 
subcutaneous granulomas or atherosclerotic plaques actively express several MMPs that are also 
secreted by non-foamy macrophages. Adaptive immunity seems to have little impact on 
macrophage polarization and increasing levels of MMPs in mice, implying a more prominent role for 
innate immune mechanisms, including the production of CSFs, inflammatory cytokines and toll-like 
receptor ligands. Even so MMP activity must be tightly regulated because overexpression of high 
levels of fully activated MMPs is needed to provoke plaque disruption in mice. The importance of 
specific MMPs may be over or under emphasized in mice, where they are more or less abundant, 
compared to man (see Fig. 1). Hence studies in human cells and tissues should be given primary 
importance, especially if genetic approaches at a population level (such as that for MMP-12) can be 
developed to give clearer indications of causality. 
Longitudinal imaging studies lead to the striking conclusion that most vulnerable plaques go on to 
heal rather than rupture (Van Mieghem et al., 2006). Hence ulceration of human plaques is a 
relatively rare outcome that, just like any other accident, most probably occurs because of an 
unusual combination of adverse circumstances.  Plaque rupture most likely results from a ‘perfect 
storm’ caused by the synergistic local effects of multiple inflammatory mediators acting together in a 
hypoxic environment combined with the loss of inhibitory signals from nuclear hormone receptors, 
TGFβ and IL-10. The potential mediators of MMP overproduction include IL-1β, which can be 
produced in plaques in response to oxidised LDL (Williams & Tabas, 1995) and as a result of 
inflammasome activation by cholesterol crystals (Duewell et al., 2010; Rajamaki et al., 2010). The 
ongoing CANTOS clinical trial will examine the causal role of IL-1 in unstable coronary disease 
(Dinarello et al., 2012). Other pro-inflammatory mediators, including TNFα, GM-CSF and IL-6, which 
stimulate macrophages through different signalling pathways (Fig. 2) have the potential to induce 
MMPs synergistically.  Suppression of TIMP-3 expression by foam cell formation, INFγ or GM-CSF 
could be a further significant factor. Toll-like receptor ligands, the most effective stimulators of MMP 
production in vitro, are also present in the atherosclerotic plaques (Lundberg & Yan, 2011). 
Conversely, anti-inflammatory treatments including, importantly, the use of statins currently provide 
the best approach to reducing MMP activity in plaques and therefore preventing plaque rupture. In 
future it is likely that more selective treatments will be developed. These should be aimed at 
inhibiting excess production of specific MMPs, especially the collagenases MMP-1 (Libby, 2013) and 
MMP-8 (Ye, 2015) and MMP-12 (Traylor et al., 2014), whilst preserving the activity of those MMPs, 
including MMP-9, that are primarily involved in vascular repair (Newby, 2005). The widely different 
regulation of different MMPs in human macrophages that recent studies have so clearly emphasized 
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Legends to Figures 
Figure 1 Comparison of MMP and TIMP expression in human and mouse macrophages 
Human (Huang et al., 2012) and mouse (Tsaousi et al., 2016) blood monocytes were differentiated to 
macrophages for 10-14 days in the presence of M-CSF. Total RNA was extracted and mRNA levels 
were measured by quantitative reverse transcription polymerase chain reaction using standards to 
derive copy numbers of transcripts per ng RNA. Differences greater than 100 fold are noted with 
arrows. 
Figure 2 Simplified pathways of MMP and TIMP induction. 
Binding of ligands to integrins (INT), toll-like receptors (TLR) and receptors for interferons (IFN), IL-1 
(IL1R), TNF (TNFR), PGE2 (EP4), IL-6 (GP130), GM-CSF (CSFR2) provide the initial signals. These 
interact with signal transduction pathways (shown in outline only). An integrative network activates 
the phophoinositide-3 kinase (PI3K), extracellular related kinases 1/2 (ERKs), p38 MAP kinase and c-
jun N-terminal kinase (JNK), as well as the inhibitor of κB kinase2 (IKK2). These lead together to 
activation of the activator protein-1 (AP-1) and nuclear factor-κB (NF-κB) transcription factors that 
directly induce several MMPs and TIMP-1. Insulin response factors (IRFs) are also induced by this 
pathway and also through activation of janus kinase 2 (JAK2), which can cause release of IFNα,β, 
leading to autocrine actions. Other autocrine pathways are triggered by the production of 
arachidonic acid (AA) from the action of phospholipaseA2 (PLA2). This is converted to prostaglandin 
E2 (PGE2) by the consecutive action of cyclooxygenase-2 (COX-2) and prostaglandin E synthetase-1 
(PGES1). Autocrine action on EP4 receptors triggers cAMP production and activation of the cAMP 
response element binding protein (CREB) transcription factor, which induces MMPs further. 
Activation of janus kinases JAKs at the GP130 and CSFR2 receptors leads to nuclear translocation of 
signal transducer and activator of transcription-3 (STAT-3) and STAT-5, respectively. Production of 
TNFα through these pathways provides addition possibilities for autocrine feedback. 
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